MEFEDINEL Prolonged release tablet Ref.[115335] Active ingredients: Methylphenidate

Source: Health Products Regulatory Authority (ZA)  Revision Year: 2021  Publisher: Sandoz SA (Pty) Ltd<sup>1</sup>, Waterfall 5-lr, Magwa Crescent West, Waterfall City, Jukskei View, 2090 1 Company Reg. No.: 1990/001979/07

Product name and form

MEFEDINEL 18 (prolonged release tablets).

MEFEDINEL 27 (prolonged release tablets).

MEFEDINEL 36 (prolonged release tablets).

MEFEDINEL 54 (prolonged release tablets).

Pharmaceutical Form

MEFEDINEL 18: prolonged release tablets. Light yellow, round, film-coated tablet with a delivery orifice on one side.

MEFEDINEL 27: prolonged release tablets. Light grey, round, film-coated tablet with a delivery orifice on one side.

MEFEDINEL 36: prolonged release tablets. White, round, film-coated tablet with a delivery orifice on one side.

MEFEDINEL 54: prolonged release tablets. Red, round, film-coated tablet with a delivery orifice on one side.

Qualitative and quantitative composition

Each MEFEDINEL 18 (prolonged release tablet) contains 18 mg methylphenidate hydrochloride.

Each MEFEDINEL 27 (prolonged release tablet) contains 27 mg methylphenidate hydrochloride.

Each MEFEDINEL 36 (prolonged release tablet) contains 36 mg methylphenidate hydrochloride.

Each MEFEDINEL 54 (prolonged release tablet) contains 54 mg methylphenidate hydrochloride.

MEFEDINEL 18 contains sugar (6,31 mg lactose monohydrate per tablet).

MEFEDINEL 27 contains sugar (8,17 mg lactose monohydrate per tablet).

MEFEDINEL 36 contains sugar (8,43 mg lactose monohydrate per tablet).

MEFEDINEL 54 contains sugar (6,76 mg lactose monohydrate per tablet).

For full list of excipients, see section 6.1.

Active Ingredient

Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space.

List of Excipients

Polyethylene oxide
Succinic acid
Povidone
Butylhydroxytoluene
Stearic acid
Sodium chloride
Iron oxide red
Cellulose acetate
Poloxamer
Hypromellose
Lactose monohydrate
Titanium dioxide
Macrogol

In addition:

MEFEDINEL 18, 54: Iron oxide yellow

MEFEDINEL 27: Iron oxide black

Pack sizes and marketing

MEFEDINEL 18, 27, 36, 54: HDPE bottles closed with a child-resistant, tamper evident PP screw cap with drying plug.

Pack sizes of 28, 30, 50, 56, 60, 98, 100 or 120 prolonged-release tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Sandoz SA (Pty) Ltd1, Waterfall 5-lr, Magwa Crescent West, Waterfall City, Jukskei View, 2090

1 Company Reg. No.: 1990/001979/07

Marketing authorization dates and numbers

MEFEDINEL 18: 48/1.2/0092
MEFEDINEL 27: 48/1.2/0093
MEFEDINEL 36: 48/1.2/0094
MEFEDINEL 54: 48/1.2/0095

Date of first authorisation: 02 February 2021

Drugs

Drug Countries
MEFEDINEL South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.